BLPH — Bellerophon Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $0.69m
- -$3.70m
- 20
- 81
- 37
- 43
Annual balance sheet for Bellerophon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 16.6 | 9.87 | 47.6 | 24.7 | 6.92 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17.4 | 10.4 | 48.1 | 25.5 | 7.56 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.664 | 2.43 | 1.67 | 0.93 | 0.186 |
| Other Long Term Assets | |||||
| Total Assets | 18.4 | 13.1 | 50.2 | 26.9 | 7.93 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 7.54 | 7.58 | 10.4 | 5.05 | 5.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 14.5 | 9.52 | 12 | 5.26 | 5.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 3.86 | 3.59 | 38.2 | 21.6 | 2.53 |
| Total Liabilities & Shareholders' Equity | 18.4 | 13.1 | 50.2 | 26.9 | 7.93 |
| Total Common Shares Outstanding |